These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32126120)

  • 1. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
    Yang JC; Roman-Urrestarazu A; Brayne C
    PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
    Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
    J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial factors and the implementation of medications for treating opioid use disorders.
    Knudsen HK; Roman PM
    J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 6. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid Use Disorder and Pregnancy.
    O'Donnell FT; Jackson DL
    Mo Med; 2017; 114(3):181-186. PubMed ID: 30228577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
    Mojtabai R; Mauro C; Wall MM; Barry CL; Olfson M
    Health Aff (Millwood); 2019 Jan; 38(1):14-23. PubMed ID: 30615514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
    Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
    J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.
    Van Zee A; Fiellin DA
    Am J Public Health; 2019 Mar; 109(3):393-394. PubMed ID: 30726142
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of County Opioid Epidemic Severity to Changes in Access to Substance Use Disorder Treatment, 2009-2017.
    Yarbrough CR; Abraham AJ; Adams GB
    Psychiatr Serv; 2020 Jan; 71(1):12-20. PubMed ID: 31575353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
    Maas J; Barton G; Maskrey V; Pinto H; Holland R
    Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.